Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Tax Provisions (2016 - 2025)

Voyager Therapeutics' Tax Provisions history spans 6 years, with the latest figure at $9000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions fell 98.46% year-over-year to $9000.0; the TTM value through Dec 2025 reached $144000.0, down 78.35%, while the annual FY2025 figure was $144000.0, 78.35% down from the prior year.
  • Tax Provisions for Q4 2025 was $9000.0 at Voyager Therapeutics, down from $83000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $822000.0 in Q4 2023 and bottomed at -$177000.0 in Q3 2023.
  • The 3-year median for Tax Provisions is $40000.0 (2024), against an average of $184750.0.
  • The largest YoY upside for Tax Provisions was 164.29% in 2025 against a maximum downside of 98.46% in 2025.
  • A 3-year view of Tax Provisions shows it stood at $822000.0 in 2023, then fell by 28.95% to $584000.0 in 2024, then plummeted by 98.46% to $9000.0 in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Tax Provisions are $9000.0 (Q4 2025), $83000.0 (Q3 2025), and $15000.0 (Q2 2025).